Bing Sui Chen

US Patent:

20090217401, Aug 27, 2009

Filed:

May 2, 2006

Appl. No.:

11/913217

Inventors:

Alan J. Korman - Piedmont CA, US
Mohan Srinivasan - San Jose CA, US
Changyu Wang - Fremont CA, US
Mark J. Selby - San Francisco CA, US
Bing Chen - Alameda CA, US
Josephine M. Cardarelli - San Carlos CA, US

Assignee:

MEDAREX, INC - Princeton NJ

International Classification:

A01K 67/027
A61K 39/395
C07H 21/00
C12N 15/74
C12N 5/10
C12N 5/16
C07K 16/18
A61P 35/00

US Classification:

800 18, 53038815, 4241421, 536 2353, 4353201, 435325, 435326, 530402

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

US Patent:

20130133091, May 23, 2013

Filed:

Aug 15, 2011

Appl. No.:

13/210137

Inventors:

Alan J. Korman - Piedmont CA, US
Mohan Srinivasan - San Jose CA, US
Changyu Wang - Fremont CA, US
Mark J. Sellby - San Francisco CA, US
Bing Chen - Alameda CA, US
Josephine M. Cardarelli - San Carlos CA, US
Haichun Huang - San Carlos CA, US

Assignee:

Ono Pharmaceutical Co., LTD. - Osaka
Medarex, Inc. - Princeton NJ

International Classification:

C07K 16/18

US Classification:

800 18, 4353201, 435332, 435 696, 536 2353

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.